Prof. GÜNEŞ ESENDAĞLI

Publication Network

Articles 114

1. Targeting endoplasmic reticulum export disrupts metabolic resilience in multiple myeloma

Horzum U., Oberacher H., Haun M., Geley S., Roman-Trufero M., Auner H., et al.

Signal Transduction and Targeted Therapy , vol.11, no.1, 2026 (SCI-Expanded, Scopus)

2. CD44-targeted cyclodextrin-hyaluronic acid nanoparticles carrying gemcitabine and paclitaxel to pancreatic cancer

VARAN G., Demirtürk N., Gökşen S., Benito J. M., Malanga M., ÖZTÜRK S. C., et al.

European Journal of Pharmaceutical Sciences , vol.221, 2026 (SCI-Expanded, Scopus)

3. Inhalable Lyophilized Dry Powder of Tumor-Targeted Gefitinib-Loaded Albumin Nanoparticles for Non Small Cell Lung Cancer Treatment

Geyık M., Bebek G., Bılal M. N., Nacak B., Temel T., Recber T., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.1, no.1, pp.1, 2026 (SCI-Expanded, Scopus)

4. Clinical significance of CD27+CD28+ effector memory T cells as potential prognostic biomarkers in ovarian cancer

Uluturk S., Aras I. A., Altahhan V., Sakar V., Karadurmus B., Hidiroglu M. M., et al.

Journal of ovarian research , vol.19, no.1, 2026 (SCI-Expanded, Scopus)

5. Alterations in PD-L1+ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model

YILMAZ K., Tavukcuoglu E., Yanik H., Seçken P., Celik E., Guler S., et al.

Medicina (Lithuania) , vol.62, no.3, 2026 (SCI-Expanded, Scopus)

6. Spaceflight alters the immune regulatory functions of neutrophil granulocytes on T lymphocytes

Tavukçuoğlu E., Yanık H., Güven H. E., Yılmaz K. B., ESENDAĞLI G.

iScience , vol.29, no.1, 2026 (SCI-Expanded, Scopus)

7. Development and in vitro/in vivo evaluation of polymeric dissolving microneedle formulation for psoriasis treatment.

Kaplan M., Arslan F. B., Öztürk S. C., Ulutürk S., Meriçöz Ç. A., Esendağlı G., et al.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences , vol.218, pp.107429, 2026 (SCI-Expanded, Scopus)

8. Detection of inflammation and glial cell-related biomarkers in adults with spinal muscular atrophy receiving nusinersen therapy

Arslan D., ERGÜL ÜLGER Z., Goksen S., Inan B., ESENDAĞLI G., ERDEM ÖZDAMAR S., et al.

Neurological Sciences , vol.47, no.1, 2026 (SCI-Expanded, Scopus)

9. Design, characterization, and in vitro/in vivo evaluation of HER2-targeted immunoliposomes co-functionalized with trastuzumab and iRGD for enhanced delivery of oxaliplatin in gastric cancer therapy

Fidan Y., Aras I. A., SİLİNDİR GÜNAY M., TİMUR S. S., ÖZTÜRK S., ESENDAĞLI G., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.113, 2025 (SCI-Expanded, Scopus) Sustainable Development

10. The impact of aspirin on PD-L1 expression and alteration of M2 polarization in non-small cell lung cancer.

Unver N., Uluturk S., Tavukcuoglu E., Duymaz Yilmaz E., Kaymaz Y., Esendagli G.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] , vol.74, no.1, pp.124, 2025 (SCI-Expanded, Scopus)

11. IL-8 contributes to functional diversity of tumor-infiltrating neutrophils: A new target for cancer immunotherapy

Tavukcuoglu E., ESENDAĞLI G.

DEVELOPMENTAL CELL , vol.60, no.3, pp.339-341, 2025 (SCI-Expanded, Scopus)

12. A Phosphatidyl Conjugated Telomerase-Dependent Telomere-Targeting Nucleoside Demonstrates Colorectal Cancer Direct Killing and Immune Signaling

YILMAZ M., Goksen S., Mender I., ESENDAĞLI G., ERDENER Ş. E., Ahmed A., et al.

BIOMOLECULES , vol.14, no.12, 2024 (SCI-Expanded, Scopus)

13. Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis

ARSLAN D., ERGÜL ÜLGER Z., Goksen S., ESENDAĞLI G., ERDEM ÖZDAMAR S., Tan E., et al.

EUROPEAN NEUROLOGY , vol.87, no.5-6, pp.223-229, 2024 (SCI-Expanded, Scopus)

14. **Development and In vitro and In vivo efficacy investigation of multifunctional, targeted, theranostic liposomes for imaging and photodynamic therapy of glioblastoma**

Onaral F. G., Silindir-Gunay M., Uluturk S., Öztürk S. C., Cakir-Aktas C., Esendagli G.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.101, 2024 (SCI-Expanded, Scopus) Sustainable Development

15. Preparation and in vitro characterization of memantine HCl loaded PLGA nanoparticles for Alzheimer's disease

Tezel G., Uluturk S., REÇBER T., TİMUR S. S., NEMUTLU E., ESENDAĞLI G., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.100, 2024 (SCI-Expanded, Scopus)

16. Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles' Biodistribution in Cancer

Goksen S., Varan G., Bilensoy E., Esendagli G.

MOLECULAR PHARMACEUTICS , vol.21, no.9, pp.4688-4699, 2024 (SCI-Expanded, Scopus) Sustainable Development

17. Evaluation of Myeloid-Derived Suppressor Cells in Newly Diagnosed MS Patients

Acar N. P., Yanik H., ESENDAĞLI G., KARABUDAK R., TUNCER M. A.

MULTIPLE SCLEROSIS JOURNAL , no.3, pp.887-888, 2024 (SCI-Expanded, Scopus)

18. Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia

Parveen M., KARAOSMANOĞLU B., SUCULARLI C., ÜNER A., TAŞKIRAN Z. E., ESENDAĞLI G.

European Journal of Immunology , vol.54, no.5, 2024 (SCI-Expanded, Scopus)

19. An all-in-one nanoparticle for overcoming drug resistance: doxorubicin and elacridar co-loaded folate receptor targeted PLGA/MSN hybrid nanoparticles.

Tonbul H., Şahin A., Öztürk S. C., Ultav G., Tavukçuoğlu E., Akbaş S., et al.

Journal of drug targeting , vol.32, pp.1101-1110, 2024 (SCI-Expanded, Scopus)

20. Immune checkpoint status and exhaustion-related phenotypes of CD8+ T cells from the tumor-draining regional lymph nodes in breast cancer

Yilmaz I., Tavukcuoglu E., Horzum U., Yilmaz K. B., Akinci M., Gulcelik M. A., et al.

Cancer Medicine , vol.12, no.24, pp.22196-22205, 2023 (SCI-Expanded, Scopus)

21. Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination

Tavukcuoglu E., Yanik H., Parveen M., Uluturk S., DURUSU TANRIÖVER M., İNKAYA A. Ç., et al.

Scientific Reports , vol.13, no.1, 2023 (SCI-Expanded, Scopus)

22. The Effect of Paclitaxel with a STAT3 Pathway Inhibitor on Metastasis in the Treatment of Triple Negative Breast Cancer

DİNÇSOY A. B., GEDİKLİ E., ÖZTÜRK S. C., Nikshiqi E., Baris V. O., KARAKOÇ E., et al.

ACTA PHYSIOLOGICA , pp.45, 2023 (SCI-Expanded, Scopus)

23. Liver resection modulates hepatic chemokine levels in breast cancer

DİNÇER H. A., Horzum U., Kursunel M. A., Yoyen-Ermis D., Ermis E., ÖZOĞUL E., et al.

Surgery (United States) , vol.174, no.2, pp.277-282, 2023 (SCI-Expanded, Scopus)

24. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors

Anthiya S., ÖZTÜRK S. C., Yanik H., Tavukcuoglu E., ŞAHİN A., Datta D., et al.

Journal of Controlled Release , vol.357, pp.67-83, 2023 (SCI-Expanded, Scopus)

25. The synthesis and anti-cancer efficacy of endoperoxide modified copper sulfide-ferritin nanocages as PDT and PTT agents

Kucukoflaz M., Ulusoy S., Korkmaz B., ÖZTÜRK S. C., AKYOL M., Hayta S. B., et al.

Journal of Nanoparticle Research , vol.25, no.4, 2023 (SCI-Expanded, Scopus)

26. A positive feedback loop driven by fibronectin and IL-1β sustains the inflammatory microenvironment in breast cancer

TUNALI G., Yanik H., ÖZTÜRK S. C., DEMİRKOL CANLI S., Efthymiou G., Yilmaz K. B., et al.

Breast cancer research : BCR , vol.25, no.1, pp.27, 2023 (SCI-Expanded, Scopus)

27. A novel combination for the treatment of small cell lung cancer: Active targeted irinotecan and stattic co-loaded PLGA nanoparticles

Arslan F. B., ÖZTÜRK K., Tavukçuoğlu E., ÖZTÜRK S. C., ESENDAĞLI G., ÇALIŞ S.

International Journal of Pharmaceutics , vol.632, 2023 (SCI-Expanded, Scopus)

28. Effects of Particle Geometry for PLGA-Based Nanoparticles: Preparation and In Vitro/In Vivo Evaluation

Kaplan M., ÖZTÜRK K., ÖZTÜRK S. C., Tavukçuoğlu E., ESENDAĞLI G., ÇALIŞ S.

Pharmaceutics , vol.15, no.1, 2023 (SCI-Expanded, Scopus)

29. Characterization of serum extracellular vesicles and their differential level of miR-197-3p in familial Mediterranean fever patients

Tavukcuoglu Z., AKKAYA ULUM Z. Y., YERSAL N., Horzum U., AKBABA T. H., KARADAĞ Ö., et al.

Nucleosides, Nucleotides and Nucleic Acids , 2023 (SCI-Expanded, Scopus)

30. Pro-fibrogenic and adipogenic aspects of chronic muscle degeneration are contributed by distinct stromal cell subpopulations

ÖZDEMİR SAKA C., Akçay D., Yöyen-Ermiş D., Taşkıran E. Z., Soylu-Kucharz R., ESENDAĞLI G., et al.

PloS one , vol.18, no.7, 2023 (SCI-Expanded, Scopus)

31. Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression.

Unver N., Tavukcuoglu E., Esendagli G.

Life sciences , vol.311, pp.121171, 2022 (SCI-Expanded, Scopus)

32. Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion

Horzum U., Yanik H., Taskiran E. Z., Esendagli G.

IMMUNOLOGY , vol.167, no.4, pp.640-650, 2022 (SCI-Expanded, Scopus)

33. Memory T cell responses in seronegative older adults following SARS-CoV-2 vaccination.

Hafızoğlu M., Bas A. O., Tavukçuoğlu E., Sahiner Z., Oytun M. G., Ulutürk S., et al.

Clinical immunology communications , vol.2, pp.154-158, 2022 (TRDizin)

34. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes

KURŞUNEL M. A., Taskiran E. Z., Tavukcuoglu E., Yanik H., Demirag F., KARAOSMANOĞLU B., et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY , vol.71, no.2, pp.445-459, 2022 (SCI-Expanded, Scopus)

35. Therapeutic efficacy and gastrointestinal biodistribution of polycationic nanoparticles for oral camptothecin delivery in early and late-stage colorectal tumor-bearing animal model

Unal S., ÖZTÜRK S. C., BİLGİÇ E., Yanik H., KORKUSUZ P., AKTAŞ Y., et al.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS , vol.169, pp.168-177, 2021 (SCI-Expanded, Scopus) Sustainable Development

36. Development of curcumin and docetaxel co-loaded actively targeted PLGA nanoparticles to overcome blood brain barrier

Seko I., TONBUL H., Tavukcuoglu E., Sahin A., AKBAŞ S., Yanik H., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.66, 2021 (SCI-Expanded, Scopus)

37. Functional responsiveness of memory T cells from COVID-19 patients

Tavukcuoglu E., Horzum U., İNKAYA A. Ç., ÜNAL S., ESENDAĞLI G.

CELLULAR IMMUNOLOGY , vol.365, 2021 (SCI-Expanded, Scopus) Sustainable Development

38. Proerythroblast Cells of Diamond-Blackfan Anemia Patients With RPS19 and CECR1 Mutations Have Similar Transcriptomic Signature

KARAOSMANOĞLU B., KURŞUNEL M. A., ÇETİNKAYA F. D., GÜMRÜK F., ESENDAĞLI G., ÜNAL Ş., et al.

FRONTIERS IN PHYSIOLOGY , vol.12, 2021 (SCI-Expanded, Scopus)

39. Folic acid decoration of mesoporous silica nanoparticles to increase cellular uptake and cytotoxic activity of doxorubicin in human breast cancer cells

TONBUL H., Sahin A., Tavukcuoglu E., Ultav G., AKBAŞ S., AKTAŞ Y., et al.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.63, 2021 (SCI-Expanded, Scopus) Sustainable Development

40. A robust optimization approach for the breast cancer targeted design of PEtOx-b-PLA polymersomes

ÖZ U. C., Bolat Z. B., Ozkose U. U., Gulyuz S., KÜÇÜKTÜRKMEN B., PARLAK KHALİLY M., et al.

MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS , vol.123, 2021 (SCI-Expanded, Scopus) Sustainable Development

41. Clinical Relevance of Polymorphonuclear Myeloid-Derived Suppressor Cells in Autoimmune-Blistering Disorders Pemphigus Vulgaris and Bullous Pemphigoid

Oktem A., Horzum U., Ertop P., KUNDAKCI N., Akay B. N., Yalcin B., et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY , vol.141, no.3, pp.672-676, 2021 (SCI-Expanded, Scopus)

42. Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: Analyses in 3D tumor culture and tumor-bearing animals in vivo

Varan G., Varan C., Öztürk S. C., Benito J. M., Esendağlı G., Bilensoy E.

Nanomaterials , vol.11, no.2, pp.1-18, 2021 (SCI-Expanded, Scopus)

43. CD66b(+)monocytes represent a proinflammatory myeloid subpopulation in cancer

Horzum U., Yoyen-Ermis D., Taskiran E. Z., Yilmaz K. B., HAMALOĞLU E., KARAKOÇ D., et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY , vol.70, no.1, pp.75-87, 2021 (SCI-Expanded, Scopus) Sustainable Development

44. Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer

Karpuz M., Silindir-Gunay M., Ozer A. Y., Ozturk S. C., Yanik H., Tuncel M., et al.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , vol.156, 2021 (SCI-Expanded, Scopus) Sustainable Development

45. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer

Tavukcuoglu E., Horzum U., Yanik H., ÜNER A., Yoyen-Ermis D., NURAL S. K., et al.

EUROPEAN JOURNAL OF IMMUNOLOGY , vol.50, no.12, pp.2067-2074, 2020 (SCI-Expanded, Scopus) Sustainable Development

46. An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy

Acar N. P., Tuncer A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., et al.

JOURNAL OF NEUROIMMUNOLOGY , vol.347, 2020 (SCI-Expanded, Scopus)

47. Design and synthesis of novel peptidomimetics for cancer immunotherapy

Kose C., Uysal E., Yazici B., Tugay Z., Dingis-Birgul S. I., Yanik H., et al.

ORGANIC COMMUNICATIONS , vol.13, no.3, pp.89-102, 2020 (ESCI, Scopus, TRDizin)

48. Development and in vitro evaluation of temozolomide-loaded PLGA nanoparticles in a thermoreversible hydrogel system for local administration in glioblastoma multiforme

Sayiner O., Arisoy S., ÇOMOĞLU T., Ozbay F. G., ESENDAĞLI G.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.57, 2020 (SCI-Expanded, Scopus)

49. Design and in vitro evaluation of folate-targeted, co-drug encapsulated theranostic liposomes for non-small cell lung cancer

KARPUZ M., Silindir-Gunay M., Kursunel M. A., ESENDAĞLI G., DOĞAN A., ÖZER A. Y.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.57, 2020 (SCI-Expanded, Scopus) Sustainable Development

50. Transcriptional splice variants of CD40 and its prognostic value in breast cancer.

Ünver N., Yöyen E., Weber B., Esendağli G.

Turkish journal of biology = Turk biyoloji dergisi , vol.44, pp.73-81, 2020 (SCI-Expanded, Scopus, TRDizin)

51. Combination of Paclitaxel and R-flurbiprofen loaded PLGA nanoparticles suppresses glioblastoma growth on systemic administration

Caban-Toktas S., Sahin A., Lule S., Esendagli G., Vural İ., Karlı Oguz K., et al.

International Journal of Pharmaceutics , vol.578, 2020 (SCI-Expanded, Scopus)

52. Development and in vitro evaluation of a new adjuvant system containing Salmonella Typhi porins and chitosan

YÜKSEL S., PEKCAN M., PURALI N., ESENDAĞLI G., Tavukcuoglu E., Rivero-Arredondo V., et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.578, 2020 (SCI-Expanded, Scopus) Sustainable Development

53. Aggregation of chitosan nanoparticles in cell culture: Reasons and resolutions

Ozturk K., Arslan F. B., Tavukcuoglu E., ESENDAĞLI G., ÇALIŞ S.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.578, 2020 (SCI-Expanded, Scopus) Sustainable Development

54. PD-L2(+) wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses

Tavukcuoglu E., Horzum U., Yilmaz K. B., ESENDAĞLI G.

IMMUNOLOGY AND CELL BIOLOGY , vol.98, no.2, pp.152-164, 2020 (SCI-Expanded, Scopus)

55. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation

Cassetta L., Bruderek K., Skrzeczynska-Moncznik J., Osiecka O., Hu X., Rundgren I. M., et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.8, no.2, 2020 (SCI-Expanded, Scopus)

56. Protocol to assess the suppression of T-cell proliferation by human MDSC

Bruger A. M., Vanhaver C., Bruderek K., Amodio G., Tavukcuoglu E., ESENDAĞLI G., et al.

TUMOR IMMUNOLOGY AND IMMUNOTHERAPY - CELLULAR METHODS, PT B , vol.632, pp.155-192, 2020 (SCI-Expanded, Scopus)

57. Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer

Tonbul H., Sahin A., Tavukcuoglu E., ESENDAĞLI G., ÇAPAN Y.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.54, 2019 (SCI-Expanded, Scopus) Sustainable Development

58. A method for high-purity isolation of neutrophil granulocytes for functional cell migration assays

Avci E., Akkaya-Ulum Y. Z., Yoyen-Ermis D., ESENDAĞLI G., Balci-Peynircioglu B.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI , vol.44, no.6, pp.810-821, 2019 (SCI-Expanded, Scopus, TRDizin)

59. Identification of circulating MOG-specific B cells in patients with MOG antibodies

Winklmeier S., Schlueter M., Spadaro M., Thaler F. S., Vural A., Gerhards R., et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION , vol.6, no.6, 2019 (SCI-Expanded, Scopus)

60. Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS

Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., et al.

SCIENTIFIC REPORTS , vol.9, 2019 (SCI-Expanded, Scopus)

61. Primary tumor resection for initially staged IV breast cancer An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival

Erol T., İmamoğlu N., Aydin B., Taşkiran Z. E., Esendağli G., Kösemehmetoğlu K., et al.

MEDICINE , vol.98, no.33, 2019 (SCI-Expanded, Scopus)

62. Dual actions of the antioxidant chlorophyllin, a glutathione transferase P1-1 inhibitor, in tumorigenesis and tumor progression

Özcan M., Esendağli G., Musdal Y., Canpinar H., Bacanli M., Anlar H. G., et al.

JOURNAL OF CELLULAR BIOCHEMISTRY , vol.120, no.5, pp.7045-7055, 2019 (SCI-Expanded, Scopus) Sustainable Development

63. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions

Bruger A. M., Dorhoi A., ESENDAĞLI G., Barczyk-Kahlert K., van der Bruggen P., Lipoldova M., et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY , vol.68, no.4, pp.631-644, 2019 (SCI-Expanded, Scopus) Sustainable Development

64. Efficacy of a novel LyP-1-containing self-microemulsifying drug delivery system (SMEDDS) for active targeting to breast cancer

TİMUR S. S., Yoyen-Ermis D., Esendagli G., Yonat S., Horzum U., ESENDAĞLI G., et al.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS , vol.136, pp.138-146, 2019 (SCI-Expanded, Scopus)

65. A Novel Missense LIG4 Mutation in a Patient With a Phenotype Mimicking Behcet's Disease

Taskiran E., Sonmez H., Kosukcu C., Tavukcuoglu E., Yazici G., Esendagli G., et al.

JOURNAL OF CLINICAL IMMUNOLOGY , vol.39, no.1, pp.99-105, 2019 (SCI-Expanded, Scopus)

66. Dual Effect of Glucocorticoid-Induced Tumor Necrosis Factor-Related Receptor Ligand Carrying Mesenchymal Stromal Cells on Small Cell Lung Cancer: A Preliminary in vitro Study

KÖPRÜ C. Z., Cagnan I., AKAR İ., ESENDAĞLI G., KORKUSUZ P., Gunel-Ozcan A.

CYTOTHERAPY , vol.20, no.7, pp.930-940, 2018 (SCI-Expanded, Scopus) Sustainable Development

67. The fibrogenic activation kinetics of stromal stem cells in three different skeletal muscle degeneration models

Ozdemir C., Akcay D., Ermis D. Y., ESENDAĞLI G., Kocaefe C.

FEBS OPEN BIO , vol.8, pp.93, 2018 (SCI-Expanded, Scopus)

68. Tumor-Induced Myeloid Cells Are Reduced by Gemcitabine-Loaded PAMAM Dendrimers Decorated with Anti-Flt1 Antibody

Yoyen-Ermis D., Ozturk-Atar K., KURŞUNEL M. A., Aydin C., Ozkazanc D., Gurbuz M. U., et al.

MOLECULAR PHARMACEUTICS , vol.15, no.4, pp.1526-1533, 2018 (SCI-Expanded, Scopus) Sustainable Development

69. Impact of repeated abdominal surgery on wound healing and myeloid cell dynamics

ESENDAĞLI G., Yoyen-Ermis D., Guseinov E., Aras C., Aydin C., ÜNER A., et al.

JOURNAL OF SURGICAL RESEARCH , vol.223, pp.188-197, 2018 (SCI-Expanded, Scopus)

70. Therapeutic efficacy of folate receptor-targeted amphiphilic cyclodextrin nanoparticles as a novel vehicle for paclitaxel delivery in breast cancer

ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., Esendagli-Yilmaz G., Yoyen-Ermis D., Erdogdu B., et al.

JOURNAL OF DRUG TARGETING , vol.26, no.1, pp.66-74, 2018 (SCI-Expanded, Scopus) Sustainable Development

71. Development of novel self-assembled polymeric micelles from partially hydrolysed poly(2-ethyl-2-oxazoline)-co-PEI-b-PCL block copolymer as non-viral vectors for plasmid DNA in vitro transfection

Kara A., Ozturk N., ESENDAĞLI G., Ozkose U. U., Gulyuz S., Yilmaz O., et al.

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY , vol.46, 2018 (SCI-Expanded, Scopus)

72. A Co-Inhibitory Alliance in Myeloid Leukemia: TIM-3/Galectin-9 Complex as a New Target for Checkpoint Blockade Therapy

KURŞUNEL M. A., ESENDAĞLI G.

EBIOMEDICINE , vol.23, pp.6-7, 2017 (SCI-Expanded, Scopus)

73. Effect of Usnic Acid/Paclitaxel Co-Administration on Mouse (4T1) Breast Cancer Cell Lines

DİNÇSOY A. B., Ermis D. Y., CANSARAN DUMAN D., TUNCER M., KARABULUT İ., ESENDAĞLI G.

ACTA PHYSIOLOGICA , vol.221, pp.40-41, 2017 (SCI-Expanded, Scopus)

74. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers

Ozturk K., ESENDAĞLI G., Gurbuz M. U., TÜLÜ M., ÇALIŞ S.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.517, pp.157-167, 2017 (SCI-Expanded, Scopus) Sustainable Development

75. Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis

Sevmis M., Yoyen-Ermis D., Aydin C., BİLGİÇ E., KORKUSUZ P., ÜNER A., et al.

IMMUNOLOGICAL INVESTIGATIONS , vol.46, no.7, pp.663-676, 2017 (SCI-Expanded, Scopus) Sustainable Development

76. Tümörlerde Doğal İmmün Yanıt

ÖZMEN F., ESENDAĞLI G.

Turkiye Klinikleri J Med Oncol-Special Topics , vol.10, pp.104-111, 2017 (Peer-Reviewed Journal)

77. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery

ŞAHİN A., ESENDAĞLI G., YERLİKAYA F., Caban-Toktas S., Yoyen-Ermis D., HORZUM U., et al.

ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY , vol.45, no.8, pp.1657-1664, 2017 (SCI-Expanded, Scopus)

78. Th1 cells in cancer-associated inflammation

Dinc Akbulut G., Ozkazanc D., ESENDAĞLI G.

TURKISH JOURNAL OF BIOLOGY , vol.41, no.1, pp.20-30, 2017 (SCI-Expanded, Scopus, TRDizin)

79. Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells

Sahin A., Yoyen-Ermis D., Caban-Toktas S., Horzum U., AKTAŞ Y., Couvreur P., et al.

JOURNAL OF MICROENCAPSULATION , vol.34, no.7, pp.659-666, 2017 (SCI-Expanded, Scopus) Sustainable Development

80. Functional exhaustion of CD4(+) T cells induced by co-stimulatory signals from myeloid leukaemia cells

Özkazanç D., Yöyen-Ermiş D., Tavukçuoğlu E., BÜYÜKAŞIK Y., ESENDAĞLI G.

IMMUNOLOGY , vol.149, no.4, pp.460-471, 2016 (SCI-Expanded, Scopus)

81. The untold story of IFN-gamma in cancer biology

KURŞUNEL M. A., ESENDAĞLI G.

CYTOKINE & GROWTH FACTOR REVIEWS , vol.31, pp.73-81, 2016 (SCI-Expanded, Scopus) Sustainable Development

82. Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles

ERDOĞAR N., ESENDAĞLI G., Nielsen T. T., ŞEN M., ÖNER L., BİLENSOY E.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.509, pp.375-390, 2016 (SCI-Expanded, Scopus) Sustainable Development

83. Cytotoxicity and biodistribution studies on PEGylated EDA and PEG cored PAMAM dendrimers

Gurbuz M. U., Ozturk K., Erturk A. S., YOYEN-ERMIS D., ESENDAĞLI G., ÇALIŞ S., et al.

JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION , vol.27, no.16, pp.1645-1658, 2016 (SCI-Expanded, Scopus)

84. Atypical Chemokine Receptors in Cancer

sarmadi p., TUNALI G., ESENDAĞLI G.

Acta Medica , 2016 (TRDizin) Sustainable Development

85. CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC tumors.

Unver N., ESENDAGLI G., YILMAZ G., GUC D.

Cytokine , vol.75, pp.330-7, 2015 (SCI-Expanded, Scopus)

86. Immune system in cancer and hydatid disease: cross-reactivity vs. immune modulation

ESENDAĞLI G., ABBASOĞLU O.

PARASITE IMMUNOLOGY , vol.37, no.8, pp.427-428, 2015 (SCI-Expanded, Scopus) Sustainable Development

87. Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma

DOLEN Y., GÜNAYDIN G., ESENDAĞLI G., Guc D.

CELLULAR IMMUNOLOGY , vol.295, no.1, pp.29-35, 2015 (SCI-Expanded, Scopus)

88. Promotion of experimental autoimmune encephalomyelitis upon neutrophil granulocytes' stimulation with formyl-methionyl-leucyl-phenylalanine (fMLP) peptide

KILIÇ A., ESENDAĞLI G., SAYAT G., TALİM B., KARABUDAK R., KURNE A.

AUTOIMMUNITY , vol.48, no.6, pp.423-428, 2015 (SCI-Expanded, Scopus)

89. Co-existence of Echinococcus granulosus infection and cancer metastasis in the liver correlates with reduced Th1 immune responses

Turhan N., ESENDAĞLI G., Ozkayar O., Tunali G., SÖKMENSÜER C., ABBASOĞLU O.

PARASITE IMMUNOLOGY , vol.37, no.1, pp.16-22, 2015 (SCI-Expanded, Scopus)

90. CRAM-A indicates IFN-gamma-associated inflammatory response in breast cancer

SARMADI P., Tunali G., Esendagli-Yilmaz G., YILMAZ K. B., ESENDAĞLI G.

MOLECULAR IMMUNOLOGY , vol.68, no.2, pp.692-698, 2015 (SCI-Expanded, Scopus) Sustainable Development

91. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands

Karasar P., ESENDAĞLI G.

BREAST CANCER RESEARCH AND TREATMENT , vol.145, no.3, pp.605-614, 2014 (SCI-Expanded, Scopus)

92. Spheroid formation and invasion capacity are differentially influenced by co-cultures of fibroblast and macrophage cells in breast cancer

Rama-Esendagli D., ESENDAĞLI G., Yilmaz G., Guc D.

MOLECULAR BIOLOGY REPORTS , vol.41, no.5, pp.2885-2892, 2014 (SCI-Expanded, Scopus) Sustainable Development

93. Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line

Sengel-Turk C. T., Hascicek C., DOĞAN A., ESENDAĞLI G., Guc D., Gonul N.

JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , vol.24, no.2, pp.166-172, 2014 (SCI-Expanded, Scopus) Sustainable Development

94. A co-stimulatory trap set by myeloid leukemia cells

Esendagli G.

ONCOIMMUNOLOGY , vol.2, no.6, 2013 (SCI-Expanded, Scopus)

95. Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands

Dolen Y., ESENDAĞLI G.

EUROPEAN JOURNAL OF IMMUNOLOGY , vol.43, no.3, pp.747-757, 2013 (SCI-Expanded, Scopus)

96. Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

ESENDAĞLI G., Kurne A. T., Sayat G., Kilic A. K., Guc D., KARABUDAK R.

JOURNAL OF NEUROIMMUNOLOGY , vol.255, pp.81-84, 2013 (SCI-Expanded, Scopus)

97. The effect of granulocyte colony stimulating factor receptor gene missense single nucleotide polymorphisms on peripheral blood stem cell enrichment

CAMURDANOGLU B. Z., ESENDAĞLI G., Ozdemir E., CANPINAR H., Guc D., Kansu E.

CYTOKINE , vol.61, no.2, pp.572-577, 2013 (SCI-Expanded, Scopus)

98. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells

Sengel-Turk C. T., Hascicek C., DOĞAN A., ESENDAĞLI G., Guc D., Gonul N.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY , vol.38, no.9, pp.1107-1116, 2012 (SCI-Expanded, Scopus) Sustainable Development

99. Injectable biodegradable polymeric system for preserving the active form and delayed-release of camptothecin anticancer drugs

Mert O., ESENDAĞLI G., DOĞAN A., DEMİR A. G.

RSC ADVANCES , vol.2, no.1, pp.176-185, 2012 (SCI-Expanded, Scopus) Sustainable Development

100. Expression of chemokine-like receptor 1 (CMKLR1) on J744A.1 macrophages co-cultured with fibroblast and/or tumor cells: Modeling the influence of microenvironment

Rama D., ESENDAĞLI G., Guc D.

CELLULAR IMMUNOLOGY , vol.271, no.1, pp.134-140, 2011 (SCI-Expanded, Scopus)

101. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapy

Kurne A., Guc D., CANPINAR H., Aydin O. F., Sayat G., Yorubulut M., et al.

ACTA NEUROLOGICA SCANDINAVICA , vol.123, no.1, pp.8-12, 2011 (SCI-Expanded, Scopus)

102. Immune Compartmentalization of T cell Subsets in Chemically-induced Breast Cancer

Fahmi T., ESENDAĞLI G., Yilmaz G., Kansu E., Guc D.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY , vol.72, no.4, pp.339-348, 2010 (SCI-Expanded, Scopus) Sustainable Development

103. CD40-1C > T single nucleotide polymorphism and CD40 expression on breast tumors

Dolen Y., Yilmaz G., ESENDAĞLI G., Guler N. E., Guc D.

CYTOKINE , vol.50, no.3, pp.243-244, 2010 (SCI-Expanded, Scopus)

104. Transfection of myeloid leukaemia cell lines is distinctively regulated by fibronectin substratum

ESENDAĞLI G., CANPINAR H., DOĞAN A., Akkaya M., Kansu E., Guc D.

CYTOTECHNOLOGY , vol.61, pp.45-53, 2009 (SCI-Expanded, Scopus)

105. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors

Bilensoy E., Sarisozen C., Esendagli G., Doğan A., Aktas Y., Şen M., et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS , vol.371, pp.170-176, 2009 (SCI-Expanded, Scopus)

106. Fibronectin promotes the phorbol 12-myristate 13-acetate-induced macrophage differentiation in myeloid leukemia cells

ESENDAĞLI G., CANPINAR H., Yilmaz G., KAYMAZ F. F., Kansu E., Guc D.

INTERNATIONAL JOURNAL OF HEMATOLOGY , vol.89, no.2, pp.167-172, 2009 (SCI-Expanded, Scopus)

107. CONSTRUCTION OF BICISTRONIC B-GALACTOSIDASE REPORTER PLASMIDS FOR EUKARYOTIC EXPRESSION OF CD40 LIGAND (CD40L) GENE

Dolen Y., ESENDAĞLI G., Oskay S., Guc D.

IUBMB LIFE , vol.61, no.3, pp.335, 2009 (SCI-Expanded, Scopus)

108. Primary tumor cells obtained from MNU-induced mammary carcinomas show immune heterogeneity which can be modulated by low-efficiency transfection of CD40L gene

ESENDAĞLI G., CANPINAR H., Yilmaz G., Gunel-Ozcan A., Guc M. O., Kansu E., et al.

CANCER BIOLOGY & THERAPY , vol.8, no.2, pp.136-142, 2009 (SCI-Expanded, Scopus)

109. Molecular and functional analysis of a novel recombinant clone of rat (Rattus norvegicus) CD40 ligand (CD40L) gene

ESENDAĞLI G., Gunel-Ozcan A., CANPINAR H., Guc D.

MOLECULAR BIOLOGY REPORTS , vol.36, no.1, pp.83-89, 2009 (SCI-Expanded, Scopus)

110. Coexistence of different tissue tumourigenesis in an N-methyl-N-nitrosourea-induced mammary carcinoma model: a histopathological report in Sprague-Dawley rats

ESENDAĞLI G., Yilmaz G., CANPINAR H., Gunel-Ozcan A., Guc M. O., Guc D.

LABORATORY ANIMALS , vol.43, no.1, pp.60-64, 2009 (SCI-Expanded, Scopus)

111. Adhesion of beta1 integrin to fibronectin regulates CAM-DR phenotype via p21(WAF1/cip1) in HL60 acute myeloid leukemia (AML) cells

CANPINAR H., ESENDAĞLI G., Kansu E., Ozcan A. G., Guc D.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.38, no.2, pp.97-104, 2008 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

112. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer

Esendagli G., Bruderek K., Goldmann T., Busche A., Branscheid D., Vollmer E., et al.

LUNG CANCER , vol.59, no.1, pp.32-40, 2008 (SCI-Expanded, Scopus)

113. Salmonella typhimurium aroB encoding murine IL 18 or CD40L evaluation for gene therapy

AYDIN D., GÜNEL ÖZCAN A., MENAGER N., ESENDAĞLI G., GÜÇ M. O., HAYRAN K. M., et al.

Febs Journal , vol.273, pp.49-50, 2006 (SCI-Expanded, Scopus)

114. pTARGET vector carrying IL 18 or CD40L genes for attenuated Salmonella typhimurium mediated gene therapy

BEK D., ESENDAĞLI G., GÜNEL ÖZCAN A., GÜÇ D., GÜÇ M. O., Kansu E.

Blood , vol.102, pp.491, 2003 (SCI-Expanded, Scopus)

Papers Presented at Peer-Reviewed Scientific Conferences 68

1. Otoimmün Kökenli Merkezi Sinir Sistemi Hastaliklarinda B Hücrelerin İmmünfenotiplendirilmesi

KURAL MANGIT E., TAVUKÇUOĞLU DEMİR E., ACAR ÖZEN N. P., ESENDAĞLI G., TUNCER M. A.

12. NÖROİMMÜNOLOJİ OKULU, Cyprus (Kktc), 8 - 11 May 2025, (Summary Text)

2. Memantine Loaded Magnetic Micro/Nanomotors for the Treatment of Alzheimer’s Disease

TEZEL TEMEL G., ÖZTÜRK E., Ulutürk S., ÖZTÜRK S. C., REÇBER T., TİMUR S. S., et al.

21st International Pharmaceutical Technology Symposium, Ankara, Turkey, 09 September 2024, (Summary Text)

3. NUSİNERSEN TEDAVİSİ ALAN ERİŞKİN SPİNAL MUSKÜLER ATROFİ HASTALARINDA İNFLAMASYON VE GLİAL HÜCRE İLİŞKİLİ BİYOBELİRTEÇLERİN TESPİTİ

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.

59. Ulusal Nöroloji Kongresi, Antalya, Turkey, 13 December 2023, (Summary Text)

4. MİYASTENİK KRİZ İLE BAŞVURAN HASTALARDA YARDIMCI FOLİKÜLER T HÜCRE (TFH) VE YARDIMCI T HÜCRE 17 (TH17) İLİŞKİLİ SİTOKİNLERİN TEDAVİ ÖNCESİ VE SONRASI DEĞİŞKENLİĞİ

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.

59. Ulusal Nöroloji Kongresi, Antalya, Turkey, 13 December 2023, (Summary Text)

5. Evaluation of the Role of Glial Factors in the Pathogenesis of Spinal Muscular Atrophy

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., İNAN B., ESENDAĞLI G., ERDEM ÖZDAMAR S., et al.

2023 Neuromuscular Study Group Meeting, Orlando, United States Of America, 22 September 2023, (Summary Text)

6. Serum Cytokines Levels in Patients with Myasthenia Gravis and Their Changes After Treatment

ARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.

75th Annual Meeting of the American-Academy-of-Neurology (AAN), Boston, United States Of America, 22 April 2023, (Summary Text)

7. Antiretroviral therapy causes a reduction in T-cell exhaustion, which is preserved after switching to a new therapy regimen

Özcan B., Tavukçuoğlu E., KARA E., Horzum U., AYAN G., SÖNMEZER M. Ç., et al.

18th European AIDS Conference (EACS 2021), London, Canada, 27 October 2021, vol.1, pp.52-53, (Full Text)

8. Effects of CARMIL2 deficiency on functional and behavioral characteristics of immune cells

Yanik H., Horzum U., Aytekin E. S., Kursunel A., Tan C., Ozbek B., et al.

vol.51, pp.356, (Summary Text)

9. Büyük veriden hücre karakterizasyonuna: Transkripsiyon faktörü kataloglarınınoluşturulması

İMREN G., KARAOSMANOĞLU B., ÇELEBİ SALTIK B., ESENDAĞLI G., TAŞKIRAN Z. E.

Tıbbi Biyoloji ve Genetik Kongresi, Turkey, 27 - 30 October 2019

10. Effect of Formulation Parameters on PLGA and PLGA-PEG Nanoparticles Formulated with Double Emulsion Method

Arslan F. B., ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.

8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 October 2019

11. A Modified Cell Culture Method for Evaluation of Chitosan Nanoparticles

ÖZTÜRK K., Arslan F. B., Tavukçuoğlu E., ESENDAĞLI G., ÇALIŞ S.

8th BBBB International Conference on Pharmaceutical Sciences, 14 - 16 October 2019, (Full Text)

12. Folic Acid Conjugated Mesoporous Silica Nanoparticles For Enhanced Therapeutic Efficacy of Doxorubicin İn Breast Cancer

TONBUL H., AKBAŞ S., ULTAV G., ŞAHİN A., TAVUKCUOĞLU E., AKTAŞ Y., et al.

8th BBBB Conference on Pharmaceutical Sciences, 14 - 16 October 2019, vol.1, pp.184-186, (Full Text) Sustainable Development

13. STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells

Yoyen-Ermis D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., et al.

17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, China, 19 - 23 October 2019, vol.49, pp.90, (Summary Text)

14. A positive feedback mechanism between basal-like breast cancer cells and monocytes through STAT3/IL-1 beta/fibronectin can support chronic inflammation in the tumor microenvironment

Tunali G., ESENDAĞLI G.

17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, China, 19 - 23 October 2019, vol.49, pp.486, (Summary Text) Sustainable Development

15. Circulating myelin oligodendrocyte glycoprotein (MOG)-specific B cells stratify patients with serum MOG-antibodies

Winklmeier S., Schlueter M., Spadaro M., Thaler F. S., Vural A., Gerhards R., et al.

2nd Joint Meeting of the German-Society-for-Immunology (DGfl) and the Italian-Society-of-Immunology-Clinical-Immunology-and-Allergology (SIICA), Munich, Germany, 10 - 13 September 2019, vol.49, pp.77, (Summary Text)

16. Transcriptomic and immunophenotypic analyses on natural killer cells in RRMS patients under fingolimod therapy

Acar-Ozen N. P., TUNCER A., Ozkazanc D., Ozbay F. G., KARAOSMANOĞLU B., Goksen S., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, Sweden, 11 - 13 September 2019, vol.25, pp.664-665, (Summary Text)

17. Small cell lung cancer stem cells show adaptive resistance through effectively Inducing t cell activation and modulating the expression of co-inhibitory receptor

KURŞUNEL M. A., TAŞKIRAN Z. E., ESENDAĞLI G.

International Molecular Immunology Immunogenetics Congress IV (MIMIC IV), Bursa, Turkey, 27 - 29 April 2019, pp.29, (Summary Text) Sustainable Development

18. Transcript variants of MDSC-related surface markers in breast cancer and colorectal cancer

horzum u., Yoyen-Ermis D., Yılmaz B. K., KARAKOÇ D., ESENDAĞLI G.

1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018, (Full Text) Sustainable Development

19. Analysis of spleen-derived MDSCs in pancreatic and gastric cancer patients

tavukcuoglu e., horzum u., Yoyen-Ermis D., aydın b., Yılmaz B. K., ÜNER A., et al.

1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018, (Full Text) Sustainable Development

20. Splenectomy-Induced Leukocytosis Promotes Intratumoral Accumulation of Myeloid-Derived Suppressor Cells, Angiogenesis and Metastasis

Yoyen-Ermis D., Sevmis M., Aydin C., Bilgic E., KORKUSUZ P., ÜNER A., et al.

1st European Symposium on Myeloid Regulatory Cells in Health and Disease, 1 - 03 November 2018, (Summary Text)

21. APOPTOTIC GENE THERAPY BY NOVEL DEVELOPED PARTIALLY HYDROLYSED PEtOx BASED MICELLAR NANOCARRIERS ON MCF-7 BREAST CANCER CELLS

KARA A., ÖZTÜRK N., ESENDAĞLI G., ÖZKÖSE U. U., Gulyuz S., bolat z. b., et al.

IPTS2018, 17 - 19 September 2018, (Summary Text) Sustainable Development

22. In Vitro Evaluation of Co-Loaded Drug Delivery, Theranostic Liposomes in Human Non-Small Cell Lung Cancer

KARPUZ M., KURŞUNEL M. A., SİLİNDİR GÜNAY M., DOĞAN A., ESENDAĞLI G., ÖZER A. Y.

19th International Pharmaceutical Technology Symposium, Antalya, Turkey, 17 September 2018, pp.182-183, (Full Text) Sustainable Development

23. PREPERATION, CHARACTERIZATION, CYTOTOXICITY EVALUATIONS OFFOLIC ACID CONJUGATED MESOPOROUS SILICA NANOPARTICLES

TONBUL H., ultav g., akbas s., sahin a., tavukcuoglu e., AKTAŞ Y., et al.

19th InternationalPharmaceutical Technology Symposium-IPTS 2018, 17 - 19 September 2018, (Full Text)

24. Characterization of Circulating Exosomes and Analysis of Exosomal microRNAs

zeynep t., AKKAYA ULUM Z. Y., YERSAL N., AKBABA T. H., Horzum U., ESENDAĞLI G., et al.

6th International Congress of the Molecular Biology of Association of Turkey, 5 - 08 September 2018, (Summary Text)

25. Preparation and Comparative Evaluation of Gemcitabine Loaded Polymeric Nanoparticles for Pancreatic Cancer Treatment

Arslan F. B., ÖZTÜRK K., ESENDAĞLI G., ÇALIŞ S.

45th Annual Meeting Exposition of the Controlled Release Society, 22 - 24 July 2018, (Summary Text) Sustainable Development

26. The Fibrogenic Activation Kinetics of Stromal Stem Cells in Three Different Skeletal Muscle Degeneration Models

ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., ESENDAĞLI G., KOCAEFE Y. Ç.

43rd FEBS CONGRESS, 7 - 12 July 2018, (Full Text)

27. Comparative Transcriptome Analysis of Distinct Stromal Cell Populations During Extracellular Matrix Remodeling in Skeletal Muscle

ÖZDEMİR SAKA C., AKÇAY D., YÖYEN ERMİŞ D., TAŞKIRAN Z. E., ESENDAĞLI G., KOCAEFE Y. Ç.

13th Meeting of the Mediterrranean Society of Myology, 27 - 29 June 2018, vol.37, pp.129-183, (Full Text)

28. Leptinin Spermatogonyal Kok Hucreler Uzerindeki Etkisi

YERSAL N., KÖSE S., Utku H., ESENDAĞLI G., Sinan O., KORKUSUZ P.

XIV. Ulusal Histoloji ve Embriyoloji Kongresi, Turkey, 10 May 2019 - 13 May 2018, (Summary Text)

29. Gemcitabine delivery via dendrimer carriers decorated with anti-VGFR1 antibody to target tumor-induced myeloid cells

KURŞUNEL M. A., Yoyen Ermis D., OZTURK ATAR K., AYDIN Ç., OZKAZANC D., GURBUZ M. U., et al.

Myeloid Derived Suppressor Cells:Identification and implications in Human Diseases, 16 - 18 April 2018, (Full Text)

30. Passive Targeting of Gemcitabine Using Poly(Caprolactone) Nanoparticles for Cancer Treatment

ÖZTÜRK K., Arslan F. B., ESENDAĞLI G., ÇALIŞ S.

2nd Gazi Pharma Symposium Series, 11 - 13 October 2017, (Summary Text) Sustainable Development

31. Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers

ÖZTÜRK K., ESENDAĞLI G., Gürbüz M. U., TÜLÜ M., ÇALIŞ S.

Advanced School in Nanomedicine, 25 - 28 September 2017, (Summary Text) Sustainable Development

32. Dual effects of chlorophylline on breast cancer cell proliferation in vivo and in vitro

ÖZCAN M., Musad Y., ESENDAĞLI G., CANPINAR H., AKSOY Y.

42nd Congress of the Federation-of-European-Biochemical-Societies (FEBS) on From Molecules to Cells and Back, Jerusalem, Israel, 10 - 14 September 2017, vol.284, pp.259, (Summary Text) Sustainable Development

33. Novel Folate-Conjugated Amphiphilic Cyclodextrin Nanoparticles For Paclitaxel Delivery in Recurrent Metastatic Breast Cancer

ERDOĞAR N., ESENDAĞLI G., NIELSEN T. T., ESENDAĞLI YILMAZ G., SARGON M. F., ÖNER L., et al.

Innovation in Medicine Summit-3, 11 - 13 May 2017, (Summary Text) Sustainable Development

34. NOVEL POLYMERIC MICELLES BASED ON Poly-(2-Ethyl-2-Oxazoline)-co-Poly(ethylenimine)-block-Poly(ɛ-caprolactone) PEtOx-co-PEI-b-PCL BLOCK COPOLYMER WITH VARIOUS HYDROLYSIS DEGREE TO EVALUATE THE EFFECT OF TRANSFECTION EFFICIENCY ON MCF-7 CELLS

KARA A., ÖZTÜRK N., ESENDAĞLI G., BOLAT z. b., GÜLYÜZ s., TELCİ D., et al.

AAPS 2017 NATIONAL BIOTECHNOLOGY CONGRESS, San Diego, United States Of America, 01 May 2107 - 03 May 2017, (Summary Text)

35. Increased monocytic myeloid-derived suppressor cells in small-cell lung cancer implicate interaction between small cell lung cancer cells and monocytes

KURŞUNEL M. A., Yoyen Ermis D., Horzum U., Esendagli D., ESENDAĞLI G.

Analysis and Clinical Monitoring ofMyeloid Regulatory Cells, Brno, Czech Republic, 1 - 03 March 2017, (Full Text) Sustainable Development

36. Comparing Intracellular Delivery of PLGA and Chitosan Nanoparticles Lessons and Challenges

ŞAHİN A., Yerlikaya F., AKTAŞ Y., ESENDAĞLI G., ÇAPAN Y.

GPEN 2016, 9 - 12 November 2016

37. Intracellular delivery and intraperıtoneal retention of different sized PLGA nanoparticles prepared by nanoprecipitation method

ŞAHİN A., ESENDAĞLI G., Fırat Y., Serhat K., Yöyen Ermis D., Horzum U., et al.

18th International Pharmaceutical Technology Symposium-IPTS 2016, 18 - 21 September 2016

38. The effect of fingolimod treatment on natural killer cells

Acar N. P., KARABUDAK R., Ozkazanc D., Sayat-Gurel G., ESENDAĞLI G., TUNCER A.

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.176-177, (Summary Text)

39. Effect of chlorophylline as an antioxidant molecule on glutathione and related enzymes in breast cancer model

ÖZCAN M., Beyramzadeh M., ESENDAĞLI G., AKSOY Y.

41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.408, (Summary Text) Sustainable Development

40. Active targeting of anti VEGFR 1 monoclonal antibody conjugated gemcitabine loaded dendrimers to pancreatic cancer and in vitro in vivo evaluation

ÖZTÜRK K., gurbuz u. m., TÜLÜ M., ESENDAĞLI G., ÇALIŞ S.

18th International Pharmaceutical Technology Symposium, 18 - 21 September 2016, (Summary Text) Sustainable Development

41. Costimulatory signals derived from myeloid leukemia cells contribute to functional exhaustion in CD4(+) T cells

Ozkazanc D., BÜYÜKAŞIK Y., ESENDAĞLI G.

International Congress of Immunology (ICI), Melbourne, Australia, 21 - 26 August 2016, vol.46, pp.1092-1093, (Summary Text)

42. Targeting myeloid derived suppressor cells MDSCs in pancreatic cancer by gemcitabine loaded anti VEGFR1 antibody coated dendrimers carriers

ÖZTÜRK K., yöyen ermiş d., özkazanç d., gürbüz m. u., TÜLÜ M., ÇALIŞ S., et al.

3rd International Molecular Immunology & Immunogenetics Congress MIMIC-III, 27 - 30 April 2016, (Summary Text) Sustainable Development

43. B7-H3 molekülünün küçük-hücreli akciğer kanseri için immünolojik biyobelirteç olarak değerlendirilmesi

KURŞUNEL M. A., ESENDAGLİ D., ESENDAĞLI G.

22. Ulusal Kanser Kongresi, Antalya, Turkey, 19 - 23 April 2017, (Full Text) Sustainable Development

44. THE PROTECTIVE ROLE OF CHLOROPHYLLINE Cu COMPLEX ON N METHYL N NITROSOUREA INDUCED BREAST CANCER MODEL

ÖZCAN M., BÜBER E., CEYHAN D., beyramzadeh m., BACANLI M., ESENDAĞLI G., et al.

XXVII. ULUSAL BİYOKİMYA KONGRESİ, 3 - 06 November 2015, vol.40, (Summary Text) Sustainable Development

45. Evaluation of Developed Dendrimer based Nanocarrier System for Pancreatic Cancer Therapy

ÖZTÜRK K., Gürbüz M., Tülü M., ESENDAĞLI G., ÇALIŞ S.

2015 AAPS Annual Meeting and Exposition, 25 October - 29 June 2015 Sustainable Development

46. Evaluation of Dendrimer Based Nanocarrier System for Pancreatic Cancer Therapy

ÖZTÜRK K., Gürbüz M. U., ESENDAĞLI G., TÜLÜ M., ÇALIŞ S.

2015 AAPS Annual Meeting, 25 - 29 October 2015, (Full Text) Sustainable Development

47. Immune modulatory effects of the small peptide molecules derived from CXCL chemokines

Yöyen Ermiş D., Karaşar P., ESENDAĞLI G.

World Immuneregulation meeting – IX, 18 - 21 March 2015

48. In Vitro and In Vivo Evaluation of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin Derivatives

ERDOĞAR N., TERNDRUP N., ÖNER L., ESENDAĞLI G., BİLENSOY E.

4th European Conference on Cyclodextrins (EUROCD 2015), 6 - 09 October 2015, (Summary Text)

49. Mesenchymal stem cells induce proliferation of NCI-H82 small cell lung cancer

KOPRU C. Z., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., KORKUSUZ P., ÖZCAN A.

Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-Therapy (FSGT), Helsinki, Finland, 17 - 20 September 2015, vol.26, (Summary Text) Sustainable Development

50. pCR3::GITRL transfected MSCs induce apoptotic cell death and SIVA1 expression in SCLC-21H lung cancer cell line

KOPRU C. Z., KORKUSUZ P., CAGNAN I., Akar-Soycan I., ESENDAĞLI G., ÖZCAN A.

51. Granulocytic subset of myeloid derived suppressor cells in rats with mammary carcinoma

DÖLEN Y., GÜNAYDIN G., ESENDAĞLI G., GÜÇ D.

4TH EUROPEAN CONGRESS OF IMMUNOLOGY, 6 - 09 September 2015, (Summary Text)

52. Fibronectin production in basal like breast cancer cells is regulated by pro inflammatory cytokines and may influence myeloid cell maturation

TUNALI G., ESENDAĞLI G.

4th European Congress of Immunulogy, 6 - 09 September 2015 Sustainable Development

53. Selective expression of CCRL2 transcript variants associates with inflammatory response in breast cancer

Sarmadi P., TUNALI G., YILMAZ G., Yılmaz K., ESENDAĞLI G.

4th European Congress of Immunulogy, 6 - 09 September 2015 Sustainable Development

54. The effect of co stimulatory signals derived from acute myeloid leukemia cells AML on helper T lymphocyte activation and exhaustion

OZKAZANC D., ESENDAĞLI G.

4th European Congress of Immunology, 6 - 09 September 2015

55. Nanopartiküller ile işaretli pGITRL aktarılmış mezenkimal kök hücrelerin küçük hücreli akciğer kanseri hücreleriyle görüntülenmesi

KÖPRÜ C. Z., GÜNEL ÖZCAN A., Cagnan I., AKAR SOYCAN İ., ESENDAĞLI G., KORKUSUZ P.

22.nci Elektron Mikroskopi Kongresi (EMK 2015), İstanbul, Turkey, 2 - 04 September 2015 Sustainable Development

56. Can acute myeloid leukemia cells act as myeloid derived suppressor cells for immune escape

YÖYEN ERMİŞ D., TUNALI G., KARAŞAR P., ESENDAĞLI G.

Young Investigator Workshop Immunosystem and Microenvironments Implications for Cancer Therapy, 24 - 26 August 2015, (Summary Text)

57. The protective role of chlorophylline-Cu complex on N-methyl-N-nitrosourea induced breast cancer model in Spraque Dawley Rats: glutathione and DNA damage levels

ÖZCAN M., BÜBER E., Ceyhan D., BACANLI M., Beyramzadeh M., ESENDAĞLI G., et al.

40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Germany, 4 - 09 July 2015, vol.282, pp.265, (Summary Text) Sustainable Development

58. Optimization by 32 Factorial Design of Tumor Targeted Nanoparticles for Paclitaxel Delivery with Folate conjugated Amphiphilic Cyclodextrin

ERDOĞAR N., ÖNER L., ESENDAĞLI G., NİELSEN T., BİLENSOY E.

EUFEPS Annual Meeting, 15 - 17 June 2015

59. Evaluation of Th17 cell infiltration in thymectomy materials of acetycholine receptor antibody positive myasthenia gravis patients

Bekircan Kurt E., Mehdikanova L., Öner S., ESENDAĞLI G., KARABULUT E., Kurne A.

AAN 67th Annual Meeting, 6 - 10 April 2015

60. Formyl-methionyl-leucyl-phenylalanine (fMLP) peptide as an adjuvant in experimental autoimmune encephalomyelitis (EAE): modulation of neutrophil granulocytes

KILIÇ A., Tuncer-Kurne A., ESENDAĞLI G., Sayat G., TALİM B., KARABUDAK R.

29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Copenhagen, Denmark, 2 - 05 October 2013, vol.19, pp.136, (Summary Text)

Books 1

1. Biomaterials Surface Properties: Impllications in Immune Response

ENDOĞAN TANIR T., ESENDAĞLI G., AKSOY E. A.

in: Biomaterials and Immune Response: Complications, Mechanisms and Immunomodulation, Vrana, Nihal Engin, Editor, CRC Press Taylor Francis Group, pp.121-140, 2018

Metrics

Publication

192

Publication (WoS)

133

Publication (Scopus)

113

Citation (WoS)

1884

H-Index (WoS)

Citation (Scopus)

2748

H-Index (Scopus)

Citation (Scholar)

3517

H-Index (Scholar)

Project

Thesis Advisory

Open Access

UN Sustainable Development Goals

SDG 3: GOAL 3: GOOD HEALTH AND WELL-BEING

SDG 16: GOAL 16: PEACE, JUSTICE AND STRONG INSTITUTIONS

Publications & Works